The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

INTRODUCTION: Amenamevir (ASP2151) is a nonnucleoside human herpesvirus helicase-primase inhibitor that was approved in Japan for the treatment of herpes zoster (shingles) in 2017. This article reports the results of two clinical trials that investigated the effects of renal and hepatic impairment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusawake, Tomohiro, Kowalski, Donna, Takada, Akitsugu, Kato, Kota, Katashima, Masataka, Keirns, James J., Lewand, Michaelene, Lasseter, Kenneth C., Marbury, Thomas C., Preston, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709452/
https://www.ncbi.nlm.nih.gov/pubmed/29134428
http://dx.doi.org/10.1007/s12325-017-0643-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709452/
https://www.ncbi.nlm.nih.gov/pubmed/29134428
http://dx.doi.org/10.1007/s12325-017-0643-3

Ejemplares similares